p140Cap guides personalized combination strategies with anti-PD-L1 immunotherapy in HER2+ and triple-negative breast cancer

Breast cancer is not a single disease but a collection of different conditions, each with its own behavior and response to treatment. Among the most aggressive forms are those driven by a protein called HER2 and those that lack the three most common targets for therapy, known as triple-negative breast cancer. For decades, doctors have treated these aggressive types with a combination of drugs that kill fast-growing cells, known as chemotherapy, and newer therapies that help the body's own immune system recognize and attack the tumor. However, these treatments do not work for everyone. Sometimes the immune system is too tired to fight, or the tumor has built a shield that blocks the immune cells. Finding a way to predict which patients will respond to immunotherapy, and which might need less harsh chemotherapy, remains one of the most urgent challenges in modern oncology.

A team of researchers at the University of Turin and other institutions has identified a specific protein inside breast cancer cells that acts as a switch for this immune response. This protein, called p140Cap, was already known to be present in some patients and absent in others, but its full role in the battle against cancer was unclear. The researchers discovered that when p140Cap is present, it fundamentally changes the environment around the tumor. Instead of a landscape filled with cells that suppress the immune system, the tumor becomes a place where immune soldiers, specifically T cells, can gather and function effectively. This discovery suggests that the presence of p140Cap could tell doctors which patients are ready for immunotherapy and which might be able to avoid the heavy side effects of standard chemotherapy.

To understand how this works, the scientists looked at the microscopic world inside tumors grown in mice. They found that in tumors where p140Cap was present, the immune system was already in a state of readiness. The T cells were there in large numbers, and unlike in other tumors, they were not exhausted or worn out. In many cancers, T cells become tired and stop working because the tumor sends out signals to shut them down. One of these signals comes from a protein called PD-L1, which acts like a stop sign for the immune system. The researchers observed that in tumors with p140Cap, the number of suppressive cells that carry this stop sign was significantly lower. This created a natural environment where the immune system was less blocked and more capable of attacking the cancer on its own.

The team then tested whether this natural advantage could be boosted by treatment. They treated mice with tumors containing p140Cap using a drug that blocks the PD-L1 stop sign. The result was dramatic: the tumors stopped growing and often shrank. However, when they treated mice with tumors that lacked p140Cap, the same drug had almost no effect. This confirmed that p140Cap is not just a passive marker but a key factor that determines whether a tumor is vulnerable to immunotherapy. The researchers also found that the protein works by organizing the surface of the cancer cell. It helps arrange the cell's outer layer in a way that keeps the PD-L1 stop sign available on the surface when the cell is exposed to low doses of chemotherapy. This makes the tumor cells easier for the immune system to see and target.

This finding opens the door to more personalized treatment strategies that could spare patients from unnecessary toxicity. In mice with HER2-positive tumors that contained p140Cap, the researchers found that they could stop the cancer using a combination of a drug that targets HER2 and an immunotherapy drug, without needing to add any chemotherapy at all. The tumors responded just as well as those treated with the full, heavy-handed regimen. In the case of triple-negative breast cancer, the presence of p140Cap allowed the researchers to use a much lower dose of chemotherapy combined with immunotherapy and still achieve strong results. This suggests that for patients with this specific protein, the standard high doses of chemotherapy might be reduced or even eliminated, leading to better quality of life without sacrificing the chance of a cure.

For the patients who do not have p140Cap, the story is different but still hopeful. The researchers discovered that these tumors are resistant to low-dose treatments because they lack the immune-friendly environment. However, they found a way to fix this. By using a drug that blocks a specific internal signaling pathway known as the Wnt-beta-catenin pathway, they could force the p140Cap-deficient tumors to behave as if they had the protein. This chemical intervention restored the immune system's ability to infiltrate the tumor and made it sensitive to low-dose chemotherapy and immunotherapy again. This means that even for patients who start with a resistant tumor, there may be a way to reprogram their cancer to respond to treatment.

The study also explored a new way to use immunotherapy drugs. Because p140Cap helps keep the PD-L1 stop sign on the surface of the cancer cell, the researchers tested a special version of the blocking antibody that is engineered to recruit other immune cells to destroy the tumor directly. This approach worked best in the tumors with p140Cap, where the target was abundant and accessible. It suggests that the presence of this protein could guide doctors not only on whether to use immunotherapy, but on which specific type of drug might work best.

Ultimately, this research provides a clear map for navigating the complex landscape of breast cancer treatment. It moves beyond the idea of treating all aggressive cancers the same way and instead offers a method to tailor therapy based on the molecular makeup of the tumor. By identifying the presence of p140Cap, doctors may soon be able to predict who will benefit from immunotherapy, who can safely reduce their chemotherapy, and who needs a specific combination of drugs to make the treatment work. While these findings are currently based on laboratory studies and animal models, they offer a concrete path forward for clinical trials that could one day spare patients from the worst side effects of cancer treatment while improving their chances of survival.